Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas Journal Article

   

Authors:	Yerram, P.; Reiss, S. N.; Modelevsky, L.; Gavrilovic, I. T.; Kaley, T.
Article Title:	Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas
Abstract:	Purpose: An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with recurrent or progressive high grade gliomas (HGG). Data regarding incidence of toxicity with combination bevacizumab and carmustine is limited. The purpose of this study is to compare toxicity of single agent carmustine and carmustine plus bevacizumab for patients with HGGs. Methods: This single center retrospective study at Memorial Sloan Kettering Cancer Center included pathologically confirmed HGG with age ≥ 18 years who received carmustine between January 2003 and May 2017. Results: Sixty-five patients with HGGs collectively received 110 doses of BCNU during the specified time period. Sixteen patients received single agent BCNU (30 doses); 49 patients received combination bevacizumab with BCNU (80 doses). There was no significant difference in incidence or grade of toxicity between single agent and combination therapy with respect to hepatotoxicity, leukopenia, lymphopenia, neutropenia, anemia, and thrombocytopenia. Rates of grade 3 and 4 neutropenia (20% vs 13.8%, p = 0.55) and thrombocytopenia (23.3% vs 23.8%, p = 1) did not differ between single agent BCNU versus combination therapy. When stratified based on dose (< 150 mg/m2, 150 mg/m2, > 150 mg/m2), there was no statistically significant difference between the two groups with respect to grade 3 and 4 neutropenia or thrombocytopenia. Conclusions: This is the first study to report the toxicity of carmustine with or without bevacizumab for the treatment of recurrent and refractory HGG. The addition of bevacizumab to carmustine did not increase incidence or grade of hematologic toxicity when compared to single agent carmustine. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Keywords:	adult; treatment response; aged; major clinical study; neutropenia; cancer recurrence; bevacizumab; drug efficacy; side effect; glioma; cancer grading; liver toxicity; multiple cycle treatment; anemia; leukopenia; thrombocytopenia; incidence; drug screening; pathology; retrospective study; carmustine; lymphocytopenia; glioblastoma; high grade glioma; bcnu; combination drug therapy; human; male; female; article; nitrosurea
Journal Title:	Journal of Neuro-Oncology
Volume:	145
Issue:	1
ISSN:	0167-594X
Publisher:	Springer
Date Published:	2019-10-01
Start Page:	57
End Page:	63
Language:	English
DOI:	10.1007/s11060-019-03266-0
PUBMED:	31432377
PROVIDER:	scopus
PMCID:	PMC7473758
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071245211&doi=10.1007%2fs11060-019-03266-0&partnerID=40&md5=4ef98b0f51fa2583a9da8d17e7cb7c29
Notes:	Article -- Export Date: 1 November 2019 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155457